DRD2 and schizophrenia: Our results underscore the need for greater understanding of how the drugs used to treat ADHD, which increase cortical DA neurotransmission and are typically given in school age children [74], and schizophrenia, which block DA neurotransmission (DRD2) and are often given in adolescence, [75] may alter these normal developmental trajectories.